AU2002255942B2 - N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity - Google Patents

N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity Download PDF

Info

Publication number
AU2002255942B2
AU2002255942B2 AU2002255942A AU2002255942A AU2002255942B2 AU 2002255942 B2 AU2002255942 B2 AU 2002255942B2 AU 2002255942 A AU2002255942 A AU 2002255942A AU 2002255942 A AU2002255942 A AU 2002255942A AU 2002255942 B2 AU2002255942 B2 AU 2002255942B2
Authority
AU
Australia
Prior art keywords
acetylcysteine
therapeutic
acetaminophen
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002255942A
Other languages
English (en)
Other versions
AU2002255942A1 (en
Inventor
James Andrus
Stephen C. De Rosa
Leonard A. Herzenberg
Leonore A. Herzenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26960383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002255942(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2002255942A1 publication Critical patent/AU2002255942A1/en
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY reassignment THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Request for Assignment Assignors: BioAdvantex Pharma, Inc.
Application granted granted Critical
Publication of AU2002255942B2 publication Critical patent/AU2002255942B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002255942A 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity Expired AU2002255942B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28060001P 2001-03-30 2001-03-30
US60/280,600 2001-03-30
US09/833,228 2001-04-11
US09/833,228 US6566401B2 (en) 2001-03-30 2001-04-11 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
PCT/US2002/009442 WO2002078627A2 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Publications (2)

Publication Number Publication Date
AU2002255942A1 AU2002255942A1 (en) 2003-04-03
AU2002255942B2 true AU2002255942B2 (en) 2007-07-05

Family

ID=26960383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255942A Expired AU2002255942B2 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Country Status (13)

Country Link
US (2) US6566401B2 (enExample)
EP (1) EP1379232B1 (enExample)
JP (3) JP2005508840A (enExample)
CN (1) CN100464743C (enExample)
AU (1) AU2002255942B2 (enExample)
BR (1) BR0208563A (enExample)
CA (1) CA2442168C (enExample)
ES (1) ES2550094T3 (enExample)
IL (2) IL158181A0 (enExample)
MX (1) MXPA03008904A (enExample)
NZ (1) NZ528478A (enExample)
RU (1) RU2291689C2 (enExample)
WO (1) WO2002078627A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion
EP3753561A1 (en) 2005-04-05 2020-12-23 Yale University Glutamate modulating agents in the treatment of mental disorders
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
RU2302236C2 (ru) * 2005-09-09 2007-07-10 Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
US8575217B2 (en) * 2009-03-16 2013-11-05 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
WO2011006097A2 (en) * 2009-07-10 2011-01-13 The Brigham And Women's Hospital, Inc. Methods For Treating Toxicity
CA2767833C (en) * 2009-07-15 2018-10-23 Leland Stanford, The Board Of Trustees Of The Junior University N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US20140135396A1 (en) * 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
WO2013175479A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity
SMT202200094T1 (it) 2013-12-24 2022-05-12 Univ Virginia Commonwealth Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta
EP3250196A4 (en) * 2015-01-27 2018-09-26 Florengale, LLC Healing topical composition
JP2018524287A (ja) * 2015-05-27 2018-08-30 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 造影後の膵炎のリスクを低下させるための組成物及び方法
CN115957294A (zh) 2015-05-28 2023-04-14 贝勒医学院 补充n-乙酰半胱氨酸和甘氨酸以改善谷胱甘肽水平的有益效果
WO2017122120A1 (en) * 2016-01-11 2017-07-20 Pledpharma Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
SMT202100404T1 (it) 2016-02-04 2021-09-14 Czap Research And Development Llc Veicoli di complessi di inclusione di ciclodestrine stratificati e rilascio controllato
AU2017376391B2 (en) 2016-12-15 2023-06-01 Zambon S.P.A. N-acetylcysteine for use as antibacterial agent
US11040007B2 (en) * 2017-01-24 2021-06-22 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen
EP3901620A4 (en) * 2018-12-21 2022-02-16 FUJIFILM Corporation Phototoxicity or photoallergy measurement method and reagent for use in said measurement method
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
US12357667B2 (en) 2021-07-28 2025-07-15 Pono Lifestyle, Llc Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US547457A (en) * 1895-10-08 Trolley-track
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
DE3616923A1 (de) 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
IT1248995B (it) * 1990-06-26 1995-02-11 Italfarmaco Spa Composizioni farmaceutiche a base di sali ferrosi
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
AU4399396A (en) * 1994-12-19 1996-07-10 Russinsky Limited Compounds
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
FR2744917B1 (fr) 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1141318B1 (en) * 1999-01-04 2006-07-05 Innovata PLC P450 / acetaminophen gdept for cancer treatment
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gogu et al. vol 59, 1996, 1323-1329 *

Also Published As

Publication number Publication date
IL158181A (en) 2012-04-30
JP2011225610A (ja) 2011-11-10
RU2003131876A (ru) 2005-04-10
IL158181A0 (en) 2004-03-28
ES2550094T3 (es) 2015-11-04
US20020142991A1 (en) 2002-10-03
EP1379232A2 (en) 2004-01-14
WO2002078627A3 (en) 2003-09-18
JP2005508840A (ja) 2005-04-07
WO2002078627A2 (en) 2002-10-10
EP1379232B1 (en) 2015-07-29
US20030069311A1 (en) 2003-04-10
NZ528478A (en) 2007-08-31
CN1507350A (zh) 2004-06-23
RU2291689C2 (ru) 2007-01-20
US6566401B2 (en) 2003-05-20
CN100464743C (zh) 2009-03-04
JP2015078185A (ja) 2015-04-23
CA2442168C (en) 2012-05-29
BR0208563A (pt) 2006-02-21
EP1379232A4 (en) 2008-04-23
US7723389B2 (en) 2010-05-25
MXPA03008904A (es) 2005-03-07
CA2442168A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AU2002255942B2 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
AU2002255942A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
ES2487897T3 (es) Combinaciones que consisten de inhibidores de la dipeptidilpeptidasa-IV y agentes antidiabéticos
US5474757A (en) Prevention of acetaminophen overdose toxicity with organosulfur compounds
US20050070607A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
US5248697A (en) Enhancement of glutathione levels with glutamine
US20110014285A1 (en) N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
AU2019201575A1 (en) Compositions and methods for treatment of chronic fatigue
RU2003122061A (ru) Антиатеросклеротическая композиция, содержащая каротиноиды, и способ ингибирования окисления липопротеина низкой плотности (ldl)
CA2849968A1 (en) Compositions and methods for treatment of neuropsychological deficits
US6048540A (en) Acetamenophen composition with reduced liver toxicity
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
ZA200307559B (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity.
US6441011B1 (en) Combined preparation consisting of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol
JPH0314812B2 (enExample)
Pajoumand et al. Successful treatment of acetaminophen overdose associated with hepatic failure
US20050182136A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction
Hodgson et al. Acute arsenic exposure secondary to deliberate self-poisoning with sheep dip
BR112021014509A2 (pt) Compostos de beta-lactama ou sais dos mesmos para uso na prevenção de ação prolongada ou tratamento de um transtorno de metabolismo de glicose
US20150202181A1 (en) Method of and compounds for the reduction of alcoholic hangover
Andrus et al. Cysteine/glutathione deficiency: a significant and treatable corollary of disease (a systematic literature review)
HK1173336A (en) N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: FORMER NAME: BIOADVANTEX PHARMA, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 28 MAR 2017 TO 28 NOV 2017 THE TIME IN WHICH TO PAY THE RENEWAL HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE RENEWAL HAS BEEN EXTENDED TO 28 NOV 2017

MK14 Patent ceased section 143(a) (annual fees not paid) or expired